Stock Price, News, Quote and Profile of UNIQURE NV(NASDAQ:QURE) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

UNIQURE NV

NASDAQ:QURE (12/4/2024, 2:06:05 PM)

6.11

-0.3 (-4.68%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month20.26%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap297.80M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 480 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Company Info

UNIQURE NV

Paasheuvelweg 25a

Amsterdam NOORD-HOLLAND 1105 BP

P: 31202406000

CEO: Matthew Kapusta

Employees: 480

Website: http://www.uniqure.com/

QURE News

2 days ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

13 days ago - uniQure Inc.uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...

14 days ago - Market News VideouniQure Breaks Below 200-Day Moving Average - Notable for QURE

a month ago - uniQure Inc.uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway...

UNIQURE NV (QURE)

Nasdaq Stock Screener

USA Stock Screener